Berridge C W, Dunn A J
Department of Neuroscience, University of Florida College of Medicine, Gainesville 32610.
J Neurosci. 1989 Oct;9(10):3513-21. doi: 10.1523/JNEUROSCI.09-10-03513.1989.
Exploratory behavior, measured by the time an animal spends investigating objects in a novel environment, has been shown to be sensitive to prior exposure of the animal to stressors. Using this paradigm, it was demonstrated previously that both corticotropin-releasing factor (CRF) and the alpha 2-adrenoreceptor antagonist, idazoxan, elicited stress-like decreases in exploratory behavior. Because an activation of cerebral noradrenergic systems is observed during stress, following intracerebroventricular (i.c.v.) administration of CRF, or following peripheral administration of idazoxan, the involvement of noradrenergic systems in the behavioral effect of restraint and CRF was examined. Inhibition of norepinephrine (NE) release using the alpha 2-agonist clonidine (25 micrograms/kg, i.p.) or the noradrenergic-selective neurotoxin DSP-4 antagonized the restraint-induced decrease in exploratory behavior. The combination of these 2 treatments completely prevented this effect of restraint. The alpha 1-receptor antagonist prazosin (200 micrograms/kg) also prevented the behavioral effect of restraint, whereas the alpha 1-agonist phenylephrine (50 or 100 ng, i.c.v.) decreased exploratory behavior. None of these treatments consistently altered locomotor activity as measured by the number of entries into the different compartments or the number of rears. These results implicate noradrenergic systems in the stress-related changes in this behavior, consistent with our parallel measures on the production of NE catabolites. Thus, both CRF and noradrenergic systems appear to be involved in the effect of restraint on exploratory behavior in this task. Neither DSP-4 nor prazosin had any effect on the CRF-induced decrease in exploratory behavior. However, the CRF antagonist alpha-helical CRF (20 micrograms, i.c.v.) reversed the decrease in exploratory behavior induced by phenylephrine. The most likely explanation is that the 2 systems act in tandem such that noradrenergic systems regulate the release of brain CRF via an alpha 1-adrenoreceptor. This arrangement parallels that involved in the release of hypothalamic CRF to activate the pituitary-adrenal axis. The implications of these results for research on stress-related behaviors and for the etiology of depression are discussed.
探索行为通过动物在新环境中探索物体所花费的时间来衡量,已被证明对动物先前暴露于应激源敏感。使用这种范式,先前已证明促肾上腺皮质激素释放因子(CRF)和α2-肾上腺素能受体拮抗剂咪唑克生都会引起探索行为类似应激的减少。由于在应激期间观察到脑去甲肾上腺素能系统的激活,在脑室内(i.c.v.)注射CRF后,或在外周注射咪唑克生后,研究了去甲肾上腺素能系统在束缚和CRF行为效应中的作用。使用α2-激动剂可乐定(25微克/千克,腹腔注射)或去甲肾上腺素能选择性神经毒素DSP-4抑制去甲肾上腺素(NE)释放,可拮抗束缚诱导的探索行为减少。这两种治疗方法的联合完全阻止了束缚的这种效应。α1-受体拮抗剂哌唑嗪(200微克/千克)也阻止了束缚的行为效应,而α1-激动剂去氧肾上腺素(50或100纳克,i.c.v.)则减少了探索行为。这些治疗方法均未持续改变通过进入不同隔室的次数或后肢站立次数所测量的运动活动。这些结果表明去甲肾上腺素能系统参与了这种行为中与应激相关的变化,这与我们对NE分解代谢产物产生的平行测量结果一致。因此,CRF和去甲肾上腺素能系统似乎都参与了该任务中束缚对探索行为的影响。DSP-4和哌唑嗪对CRF诱导的探索行为减少均无任何影响。然而,CRF拮抗剂α-螺旋CRF(20微克,i.c.v.)逆转了去氧肾上腺素诱导的探索行为减少。最可能的解释是这两个系统协同作用,使得去甲肾上腺素能系统通过α1-肾上腺素能受体调节脑CRF的释放。这种安排与下丘脑CRF释放以激活垂体-肾上腺轴的情况相似。讨论了这些结果对应激相关行为研究和抑郁症病因学的意义。